Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.

Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, Utikal J, Haferkamp S, Blank C, Larkin J, Garbe C, Schadendorf D, Lorigan P, Schilling B.

Eur J Cancer. 2019 Jun 15;116:207-215. doi: 10.1016/j.ejca.2019.05.015. [Epub ahead of print]

PMID:
31212163
2.

Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases.

Angela Y, Haferkamp S, Weishaupt C, Ugurel S, Becker JC, Oberndörfer F, Alar V, Satzger I, Gutzmer R.

Cancer Immunol Immunother. 2019 Jul;68(7):1187-1194. doi: 10.1007/s00262-019-02353-5. Epub 2019 Jun 11.

PMID:
31187176
3.

Role of melanoma inhibitory activity in melanocyte senescence.

Feuerer L, Lamm S, Henz I, Kappelmann-Fenzl M, Haferkamp S, Meierjohann S, Hellerbrand C, Kuphal S, Bosserhoff AK.

Pigment Cell Melanoma Res. 2019 Jun 6. doi: 10.1111/pcmr.12801. [Epub ahead of print]

PMID:
31172672
4.

Unexpected polymorphism during a catalyzed mechanochemical Knoevenagel condensation.

Haferkamp S, Paul A, Michalchuk AAL, Emmerling F.

Beilstein J Org Chem. 2019 May 21;15:1141-1148. doi: 10.3762/bjoc.15.110. eCollection 2019.

5.

Prospect of Plasmacytoid Dendritic Cells in Enhancing Anti-Tumor Immunity of Oncolytic Herpes Viruses.

Schuster P, Lindner G, Thomann S, Haferkamp S, Schmidt B.

Cancers (Basel). 2019 May 11;11(5). pii: E651. doi: 10.3390/cancers11050651. Review.

6.

Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task.

Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Holland-Letz T, Utikal JS, von Kalle C; Collaborators.

Eur J Cancer. 2019 May;113:47-54. doi: 10.1016/j.ejca.2019.04.001. Epub 2019 Apr 10.

7.

Regression eines mukosalen Melanoms unter intraläsionaler Applikation von Talimogen laherparepvec (T-Vec) in Kombination mit einer Immuntherapie.

Drescher C, Drexler K, Hilber H, Schmidt B, Haferkamp S.

J Dtsch Dermatol Ges. 2019 Mar;17(3):321-323. doi: 10.1111/ddg.13763_g. No abstract available.

PMID:
30920754
8.

A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task.

Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Fröhling S, Utikal JS, von Kalle C; Collaborators.

Eur J Cancer. 2019 Apr;111:148-154. doi: 10.1016/j.ejca.2019.02.005. Epub 2019 Mar 8.

9.

Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark.

Brinker TJ, Hekler A, Hauschild A, Berking C, Schilling B, Enk AH, Haferkamp S, Karoglan A, von Kalle C, Weichenthal M, Sattler E, Schadendorf D, Gaiser MR, Klode J, Utikal JS.

Eur J Cancer. 2019 Apr;111:30-37. doi: 10.1016/j.ejca.2018.12.016. Epub 2019 Feb 22.

10.

Regression of mucosal melanoma following intralesional talimogene laherparepvec (T-VEC) injection in combination with immunotherapy.

Drescher C, Drexler K, Hilber H, Schmidt B, Haferkamp S.

J Dtsch Dermatol Ges. 2019 Mar;17(3):321-323. doi: 10.1111/ddg.13763. Epub 2019 Jan 30. No abstract available.

PMID:
30698924
11.

Microfluidic enrichment, isolation and characterization of disseminated melanoma cells from lymph node samples.

Weidele K, Stojanović N, Feliciello G, Markiewicz A, Scheitler S, Alberter B, Renner P, Haferkamp S, Klein CA, Polzer B.

Int J Cancer. 2019 Jul 1;145(1):232-241. doi: 10.1002/ijc.32092. Epub 2019 Jan 14.

PMID:
30586191
12.

Acute on chronic anaemia with a haemoglobin of 18 g/L (1.8 g/dL) and haematocrit of 7.2.

Haferkamp SF, Cherukuri SV, Valasareddi SL, Skandhan A.

BMJ Case Rep. 2018 Dec 22;11(1). pii: e226000. doi: 10.1136/bcr-2018-226000.

PMID:
30580296
13.

Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.

Mohr P, Haferkamp S, Pinter A, Weishaupt C, Huber MA, Downey G, Öhrling K, Loquai C, Louie KS.

Adv Ther. 2019 Jan;36(1):101-117. doi: 10.1007/s12325-018-0850-6. Epub 2018 Dec 7.

14.

Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.

Brummer C, Faerber S, Bruss C, Blank C, Lacroix R, Haferkamp S, Herr W, Kreutz M, Renner K.

Cancer Lett. 2019 Feb 1;442:453-463. doi: 10.1016/j.canlet.2018.11.018. Epub 2018 Nov 24.

PMID:
30481565
15.

Hyperkeratose der Brustwarze und des Warzenhofs: eine histopathologische Falle!

Sander D, Dietmaier W, Wobser M, Haferkamp S.

J Dtsch Dermatol Ges. 2018 Nov;16(11):1368-1371. doi: 10.1111/ddg.13677_g. No abstract available.

PMID:
30395414
16.

Komplette Remission eines Patienten mit metastasierten Uveamelanom nach initialem Progress unter Immuntherapie mit Pembrolizumab.

Stauner CT, Drexler K, Berneburg M, Haferkamp S.

J Dtsch Dermatol Ges. 2018 Nov;16(11):1376-1378. doi: 10.1111/ddg.13660_g. No abstract available.

PMID:
30395409
17.

Expression of proton-sensing G-protein-coupled receptors in selected skin tumors.

Nassios A, Wallner S, Haferkamp S, Klingelhöffer C, Brochhausen C, Schreml S.

Exp Dermatol. 2019 Jan;28(1):66-71. doi: 10.1111/exd.13809. Epub 2018 Dec 13.

PMID:
30339292
18.

Complete response to pembrolizumab after initial progress in a patient with metastatic uveal melanoma.

Stauner CT, Drexler K, Berneburg M, Haferkamp S.

J Dtsch Dermatol Ges. 2018 Nov;16(11):1376-1378. doi: 10.1111/ddg.13660. Epub 2018 Oct 9. No abstract available.

PMID:
30299577
19.

Hyperkeratosis of the nipple and areola: a histopathologic pitfall.

Sander D, Dietmaier W, Wobser M, Haferkamp S.

J Dtsch Dermatol Ges. 2018 Nov;16(11):1368-1370. doi: 10.1111/ddg.13677. Epub 2018 Oct 8. No abstract available.

PMID:
30295995
20.

BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1.

Grimm J, Hufnagel A, Wobser M, Borst A, Haferkamp S, Houben R, Meierjohann S.

Oncogenesis. 2018 Sep 20;7(9):71. doi: 10.1038/s41389-018-0082-2.

21.

Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment.

Pieper N, Zaremba A, Leonardelli S, Harbers FN, Schwamborn M, Lübcke S, Schrörs B, Baingo J, Schramm A, Haferkamp S, Seifert U, Sucker A, Lennerz V, Wölfel T, Schadendorf D, Schilling B, Paschen A, Zhao F.

Oncoimmunology. 2018 Apr 18;7(8):e1450127. doi: 10.1080/2162402X.2018.1450127. eCollection 2018.

22.

Smart Medical Information Technology for Healthcare (SMITH).

Winter A, Stäubert S, Ammon D, Aiche S, Beyan O, Bischoff V, Daumke P, Decker S, Funkat G, Gewehr JE, de Greiff A, Haferkamp S, Hahn U, Henkel A, Kirsten T, Klöss T, Lippert J, Löbe M, Lowitsch V, Maassen O, Maschmann J, Meister S, Mikolajczyk R, Nüchter M, Pletz MW, Rahm E, Riedel M, Saleh K, Schuppert A, Smers S, Stollenwerk A, Uhlig S, Wendt T, Zenker S, Fleig W, Marx G, Scherag A, Löffler M.

Methods Inf Med. 2018 Jul;57(S 01):e92-e105. doi: 10.3414/ME18-02-0004. Epub 2018 Jul 17.

23.

In Situ Investigations of Mechanochemical One-Pot Syntheses.

Kulla H, Haferkamp S, Akhmetova I, Röllig M, Maierhofer C, Rademann K, Emmerling F.

Angew Chem Int Ed Engl. 2018 May 14;57(20):5930-5933. doi: 10.1002/anie.201800147. Epub 2018 Apr 17.

PMID:
29605971
24.

Single cell polarity in liquid phase facilitates tumour metastasis.

Lorentzen A, Becker PF, Kosla J, Saini M, Weidele K, Ronchi P, Klein C, Wolf MJ, Geist F, Seubert B, Ringelhan M, Mihic-Probst D, Esser K, Roblek M, Kuehne F, Bianco G, O'Connor T, Müller Q, Schuck K, Lange S, Hartmann D, Spaich S, Groß O, Utikal J, Haferkamp S, Sprick MR, Damle-Vartak A, Hapfelmeier A, Hüser N, Protzer U, Trumpp A, Saur D, Vartak N, Klein CA, Polzer B, Borsig L, Heikenwalder M.

Nat Commun. 2018 Feb 28;9(1):887. doi: 10.1038/s41467-018-03139-6.

25.

Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma.

Werner-Klein M, Scheitler S, Hoffmann M, Hodak I, Dietz K, Lehnert P, Naimer V, Polzer B, Treitschke S, Werno C, Markiewicz A, Weidele K, Czyz Z, Hohenleutner U, Hafner C, Haferkamp S, Berneburg M, Rümmele P, Ulmer A, Klein CA.

Nat Commun. 2018 Feb 9;9(1):595. doi: 10.1038/s41467-017-02674-y.

26.

Can checkpoint inhibitor therapy improve response to chemotherapy?

Kirchberger MC, Schilling B, Haferkamp S, Bosserhoff A, Schuler G, Heinzerling L.

J Cancer Res Clin Oncol. 2018 Jan;144(1):183-185. doi: 10.1007/s00432-017-2546-8. Epub 2017 Nov 24. No abstract available.

PMID:
29177557
27.

Mechanochemical Knoevenagel condensation investigated in situ.

Haferkamp S, Fischer F, Kraus W, Emmerling F.

Beilstein J Org Chem. 2017 Sep 26;13:2010-2014. doi: 10.3762/bjoc.13.197. eCollection 2017.

28.

BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.

Borst A, Haferkamp S, Grimm J, Rösch M, Zhu G, Guo S, Li C, Gao T, Meierjohann S, Schrama D, Houben R.

Cancer Lett. 2017 Sep 28;404:70-78. doi: 10.1016/j.canlet.2017.07.005. Epub 2017 Jul 15.

PMID:
28720543
29.

Membrane-binding and activation of LKB1 by phosphatidic acid is essential for development and tumour suppression.

Dogliotti G, Kullmann L, Dhumale P, Thiele C, Panichkina O, Mendl G, Houben R, Haferkamp S, Püschel AW, Krahn MP.

Nat Commun. 2017 Jun 26;8:15747. doi: 10.1038/ncomms15747.

30.

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.

Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C.

Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22.

PMID:
28648699
31.

The Role of Sumoylation in Senescence.

Scurr LL, Haferkamp S, Rizos H.

Adv Exp Med Biol. 2017;963:215-226. doi: 10.1007/978-3-319-50044-7_13. Review.

PMID:
28197915
32.

Multi-omics Analysis of Serum Samples Demonstrates Reprogramming of Organ Functions Via Systemic Calcium Mobilization and Platelet Activation in Metastatic Melanoma.

Muqaku B, Eisinger M, Meier SM, Tahir A, Pukrop T, Haferkamp S, Slany A, Reichle A, Gerner C.

Mol Cell Proteomics. 2017 Jan;16(1):86-99. doi: 10.1074/mcp.M116.063313. Epub 2016 Nov 22.

33.

Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial.

Hart C, Vogelhuber M, Hafner C, Landthaler M, Berneburg M, Haferkamp S, Herr W, Reichle A.

J Eur Acad Dermatol Venereol. 2016 Nov;30(11):e119-e121. doi: 10.1111/jdv.13391. Epub 2015 Sep 29. No abstract available.

34.

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.

Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, Kastenberger M, Bogdan C, Schleicher U, Mackensen A, Ullrich E, Fichtner-Feigl S, Kesselring R, Mack M, Ritter U, Schmid M, Blank C, Dettmer K, Oefner PJ, Hoffmann P, Walenta S, Geissler EK, Pouyssegur J, Villunger A, Steven A, Seliger B, Schreml S, Haferkamp S, Kohl E, Karrer S, Berneburg M, Herr W, Mueller-Klieser W, Renner K, Kreutz M.

Cell Metab. 2016 Nov 8;24(5):657-671. doi: 10.1016/j.cmet.2016.08.011. Epub 2016 Sep 15.

35.

RB1 is the crucial target of the Merkel cell polyomavirus Large T antigen in Merkel cell carcinoma cells.

Hesbacher S, Pfitzer L, Wiedorfer K, Angermeyer S, Borst A, Haferkamp S, Scholz CJ, Wobser M, Schrama D, Houben R.

Oncotarget. 2016 May 31;7(22):32956-68. doi: 10.18632/oncotarget.8793.

36.

Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.

Zhu G, Yi X, Haferkamp S, Hesbacher S, Li C, Goebeler M, Gao T, Houben R, Schrama D.

Cancer Lett. 2016 Jun 28;376(1):43-52. doi: 10.1016/j.canlet.2016.03.028. Epub 2016 Mar 18.

PMID:
27000992
37.

Serine 220 phosphorylation of the Merkel cell polyomavirus large T antigen crucially supports growth of Merkel cell carcinoma cells.

Schrama D, Hesbacher S, Angermeyer S, Schlosser A, Haferkamp S, Aue A, Adam C, Weber A, Schmidt M, Houben R.

Int J Cancer. 2016 Mar 1;138(5):1153-62. doi: 10.1002/ijc.29862. Epub 2015 Oct 5.

38.

In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells.

Leikam C, Hufnagel AL, Otto C, Murphy DJ, Mühling B, Kneitz S, Nanda I, Schmid M, Wagner TU, Haferkamp S, Bröcker EB, Schartl M, Meierjohann S.

Cell Death Dis. 2015 Apr 2;6:e1711. doi: 10.1038/cddis.2015.71.

39.

Characterization of functional domains in the Merkel cell polyoma virus Large T antigen.

Houben R, Angermeyer S, Haferkamp S, Aue A, Goebeler M, Schrama D, Hesbacher S.

Int J Cancer. 2015 Mar 1;136(5):E290-300. doi: 10.1002/ijc.29200. Epub 2014 Sep 19.

40.

p53 regulation by TRP2 is not pervasive in melanoma.

Houben R, Schmid CP, Maier M, Wobser M, Motschenbacher S, Becker JC, Vetter-Kauczok CS, Weyandt G, Hesbacher S, Haferkamp S.

PLoS One. 2014 Jan 27;9(1):e87440. doi: 10.1371/journal.pone.0087440. eCollection 2014.

41.

Periocular cutaneous oncocytoma with signs of disrupted oxygen metabolism.

Wobser M, Haferkamp S, Roth S, Meyer-Ter-Vehn T, Pfister A, Giner T, Rütten A, Kneitz H, Goebeler M, Geissinger E.

J Cutan Pathol. 2013 Dec;40(12):1054-8. doi: 10.1111/cup.12223. Epub 2013 Sep 20.

PMID:
24111916
42.

α-Fucosidase as a novel convenient biomarker for cellular senescence.

Hildebrand DG, Lehle S, Borst A, Haferkamp S, Essmann F, Schulze-Osthoff K.

Cell Cycle. 2013 Jun 15;12(12):1922-7. doi: 10.4161/cc.24944. Epub 2013 May 13.

43.

The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival.

Hohenauer T, Berking C, Schmidt A, Haferkamp S, Senft D, Kammerbauer C, Fraschka S, Graf SA, Irmler M, Beckers J, Flaig M, Aigner A, Höbel S, Hoffmann F, Hermeking H, Rothenfusser S, Endres S, Ruzicka T, Besch R.

EMBO Mol Med. 2013 Jun;5(6):919-34. doi: 10.1002/emmm.201201862. Epub 2013 May 13.

44.

Mechanisms of p53 restriction in Merkel cell carcinoma cells are independent of the Merkel cell polyoma virus T antigens.

Houben R, Dreher C, Angermeyer S, Borst A, Utikal J, Haferkamp S, Peitsch WK, Schrama D, Hesbacher S.

J Invest Dermatol. 2013 Oct;133(10):2453-2460. doi: 10.1038/jid.2013.169. Epub 2013 Apr 5.

45.

Vemurafenib induces senescence features in melanoma cells.

Haferkamp S, Borst A, Adam C, Becker TM, Motschenbacher S, Windhövel S, Hufnagel AL, Houben R, Meierjohann S.

J Invest Dermatol. 2013 Jun;133(6):1601-9. doi: 10.1038/jid.2013.6. Epub 2013 Feb 14.

46.

Absence of distinguishing senescence traits in human melanocytic nevi.

Tran SL, Haferkamp S, Scurr LL, Gowrishankar K, Becker TM, Desilva C, Thompson JF, Scolyer RA, Kefford RF, Rizos H.

J Invest Dermatol. 2012 Sep;132(9):2226-34. doi: 10.1038/jid.2012.126. Epub 2012 Apr 19.

47.

High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays.

Houben R, Hesbacher S, Schmid CP, Kauczok CS, Flohr U, Haferkamp S, Müller CS, Schrama D, Wischhusen J, Becker JC.

PLoS One. 2011;6(7):e22096. doi: 10.1371/journal.pone.0022096. Epub 2011 Jul 8.

48.

Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinoma.

Schrama D, Peitsch WK, Zapatka M, Kneitz H, Houben R, Eib S, Haferkamp S, Moore PS, Shuda M, Thompson JF, Trefzer U, Pföhler C, Scolyer RA, Becker JC.

J Invest Dermatol. 2011 Aug;131(8):1631-8. doi: 10.1038/jid.2011.115. Epub 2011 May 12.

49.

Oncogene-induced senescence pathways in melanocytes.

Haferkamp S, Rizos H.

Cell Cycle. 2010 Dec 15;9(24):4778-9. Epub 2010 Dec 15. No abstract available.

PMID:
21150332
50.

IGFBP7 is not required for B-RAF-induced melanocyte senescence.

Scurr LL, Pupo GM, Becker TM, Lai K, Schrama D, Haferkamp S, Irvine M, Scolyer RA, Mann GJ, Becker JC, Kefford RF, Rizos H.

Cell. 2010 May 14;141(4):717-27. doi: 10.1016/j.cell.2010.04.021.

Supplemental Content

Loading ...
Support Center